Originally published as JCO Early Release 10.1200/JCO.2004.02.109 on August 23 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hotta, K. Articles by Tanimoto, M. Search for Related Content PubMed PubMed Citation Articles by Hotta, K. Articles by Tanimoto, M. Related Articles Related Article Related Editorial Related Correspondence Social Bookmarking                            What's this?

Meta-Analysis of Randomized Clinical Trials Comparing Cisplatin to Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

From the Department of Medicine II, Okayama University Medical School, Okayama; Department of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.

Address reprint requests to Katsuyuki Hotta, MD, Department of Medicine II, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan; e-mail: khotta{at}md.okayama-u.ac.jp

PURPOSE: It remains undetermined whether cisplatin and carboplatin are equally effective for advanced non–small-cell lung cancer (NSCLC). We therefore did a meta-analysis of trials that compared cisplatin-based chemotherapy with carboplatin-based chemotherapy.

METHODS: We performed a literature search to identify trials that had investigated the substitution of carboplatin for cisplatin in the treatment of advanced NSCLC. We evaluated these trials for inclusion, rated methodologic quality, and abstracted relevant data.

RESULTS: Of 1,191 reports, eight trials (2,948 patients) were identified, five of which investigated drug regimens containing platinum plus a new agent. Cisplatin-based chemotherapy produced a higher response rate, but the survival advantage was not significant (hazard ratio = 1.050; 95% CI, 0.907 to 1.216; P = .515). Subgroup analysis revealed that combination chemotherapy consisting of cisplatin plus a new agent yields 11% longer survival than carboplatin plus the same new agent (hazard ratio = 1.106; 95% CI, 1.005 to 1.218; P = .039). Patients on cisplatin-based chemotherapy frequently developed nausea and vomiting; thrombocytopenia was more frequent during carboplatin-based chemotherapy. No significant difference in treatment-related mortality was observed.

CONCLUSION: We found that combination chemotherapy consisting of cisplatin plus a new agent yields a substantial survival advantage compared with carboplatin plus a new agent in patients with advanced NSCLC, although we failed to find any survival difference in an analysis that included both new and old agents. The strength of our conclusion is limited because we used abstracted data, and careful interpretation is thus required. Nevertheless, our results raise a critical point that needs to be evaluated in future studies.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

• Role of Adjuvant Chemotherapy in Patients With Resected Non–Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials
  Katsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, and Mitsune Tanimoto
  JCO 2004 22: 3860-3867 [Abstract] [Full Text]

Related Editorial

• Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step
  Pascal Piedbois and Marc Buyse
  JCO 2004 22: 3839-3841 [Full Text]

Related Correspondence

• They Also Serve Who Only Stand and Wait: Do Individual Clinical Researchers, Too? Hoping for Individual Patient Data As Public Domain
  Keitaro Matsuo, Katsuyuki Hotta, and Hiroshi Ueoka
  JCO 2005 23: 1334-1335 [Full Text]

This article has been cited by other articles:

				J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer Ann. Onc., March 1, 2010; 21(3): 540 - 547. [Abstract] [Full Text] [PDF]

				C. G. Azzoli, S. Baker Jr, S. Temin, W. Pao, T. Aliff, J. Brahmer, D. H. Johnson, J. L. Laskin, G. Masters, D. Milton, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer J. Clin. Oncol., December 20, 2009; 27(36): 6251 - 6266. [Abstract] [Full Text] [PDF]

				A. Hiramatsu, Y. Iwasaki, Y. Koyama, N. Tamiya, S. Hosogi, M. Nakanishi, Y. Kohno, M. Ueda, T. Arimoto, and Y. Marunaka Phase II Trial of Weekly Gemcitabine and Split-dose Cisplatin for Advanced Non-small-cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2009; 39(12): 779 - 783. [Abstract] [Full Text] [PDF]

				Y. H. Kim, K. Kubota, K. Goto, K. Yoh, S. Niho, H. Ohmatsu, N. Saijo, and Y. Nishiwaki A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 576 - 581. [Abstract] [Full Text] [PDF]

				B. H. Gronberg, R. M. Bremnes, O. Flotten, T. Amundsen, P. Fr. Brunsvig, H. H. Hjelde, S. Kaasa, C. von Plessen, F. Stornes, T. Tollali, et al. Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2009; 27(19): 3217 - 3224. [Abstract] [Full Text] [PDF]

				T. HIROSE, T. SUGIYAMA, S. KUSUMOTO, T. SHIRAI, M. NAKASHIMA, T. YAMAOKA, K. OKUDA, K. OGURA, T. OHNISHI, T. OHMORI, et al. Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer Anticancer Res, May 1, 2009; 29(5): 1733 - 1738. [Abstract] [Full Text] [PDF]

				L. Chhatwani, E. Cabebe, and H. A. Wakelee Adjuvant Treatment of Resected Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 194 - 200. [Abstract] [Full Text] [PDF]

				T. E. Stinchcombe and M. A. Socinski Current Treatments for Advanced Stage Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 233 - 241. [Abstract] [Full Text] [PDF]

				J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]

				G. M. Strauss, J. E. Herndon II, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. H. Harpole, H. H. Gillenwater, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J. Clin. Oncol., November 1, 2008; 26(31): 5043 - 5051. [Abstract] [Full Text] [PDF]

				M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652. [Abstract] [Full Text] [PDF]

				J.-P. Pignon, H. Tribodet, G. V. Scagliotti, J.-Y. Douillard, F. A. Shepherd, R. J. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group J. Clin. Oncol., July 20, 2008; 26(21): 3552 - 3559. [Abstract] [Full Text] [PDF]

				D. Morgensztern and R. Govindan Adjuvant Chemotherapy for Lung Cancer: Cisplatin Doublets Only? J Natl Compr Canc Netw, March 1, 2008; 6(3): 277 - 284. [Abstract] [PDF]

				S. Ramalingam and C. Belani Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions Oncologist, January 1, 2008; 13(suppl_1): 5 - 13. [Abstract] [Full Text] [PDF]

				C. G. Azzoli, M. G. Kris, and D. G. Pfister Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed J Natl Cancer Inst, June 6, 2007; 99(11): 828 - 829. [Full Text] [PDF]

				A. Ardizzoni, L. Boni, M. Tiseo, F. V. Fossella, J. H. Schiller, M. Paesmans, D. Radosavljevic, A. Paccagnella, P. Zatloukal, P. Mazzanti, et al. Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis J Natl Cancer Inst, June 6, 2007; 99(11): 847 - 857. [Abstract] [Full Text] [PDF]

				H. Takatani, H. Soda, Y. Nakamura, A. Kinoshita, M. Fukuda, S. Nagashima, M. Fukuda, Y. Soejima, H. Nakano, M. Oka, et al. Phase I Study of Irinotecan and Gemcitabine in Previously Untreated Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., May 1, 2007; 37(5): 353 - 357. [Abstract] [Full Text] [PDF]

				M. C. Garassino, L. Hollander, V. Torri, G. R. Oxnard, J.-P. Sculier, A.-P. Meert, M. Paesmans, G. Sonpavde, A. Sandler, R. Gray, et al. Bevacizumab for Non-Small-Cell Lung Cancer N. Engl. J. Med., March 29, 2007; 356(13): 1373 - 1375. [Full Text] [PDF]

				P Bidoli, N Zilembo, D Cortinovis, L Mariani, L Isa, E Aitini, D Cullura, F Pari, P Nova, M Mancin, et al. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study Ann. Onc., March 1, 2007; 18(3): 461 - 467. [Abstract] [Full Text] [PDF]

				H. Wakelee, S. Dubey, and D. Gandara Optimal Adjuvant Therapy for Non-Small Cell Lung Cancer--How to Handle Stage I Disease Oncologist, March 1, 2007; 12(3): 331 - 337. [Abstract] [Full Text] [PDF]

				S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer Ann. Onc., December 1, 2006; 17(12): 1810 - 1817. [Abstract] [Full Text] [PDF]

				R. Booton, P. Lorigan, H. Anderson, S. Baka, L. Ashcroft, M. Nicolson, M. O'Brien, D. Dunlop, K. O'Byrne, V. Laurence, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) Ann. Onc., July 1, 2006; 17(7): 1111 - 1119. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, J.-F. Shih, R.-P. Perng, C.-M. Tsai, and J. Whang-Peng A Randomized Trial of Different Docetaxel Schedules in Non-small Cell Lung Cancer Patients Who Failed Previous Platinum-Based Chemotherapy. Chest, April 1, 2006; 129(4): 1031 - 1038. [Abstract] [Full Text] [PDF]

				D. S. Ettinger Clinical Implications of EGFR Expression in the Development and Progression of Solid Tumors: Focus on Non-Small Cell Lung Cancer. Oncologist, April 1, 2006; 11(4): 358 - 373. [Abstract] [Full Text] [PDF]

				M. Tiseo, L. Boni, and A. Ardizzoni Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Does Cisplatin Versus Carboplatin Make a Difference? J. Clin. Oncol., September 1, 2005; 23(25): 6276 - 6277. [Full Text] [PDF]

				G. D'Addario, M. Pintilie, and F. A. Shepherd In Reply: J. Clin. Oncol., September 1, 2005; 23(25): 6277 - 6278. [Full Text] [PDF]

				B. Besse, J. C. Soria, and T. Le Chevalier Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy Ann. Onc., July 1, 2005; 16(7): 997 - 998. [Full Text] [PDF]

				C. P. Belani, J. S. Lee, M. A. Socinski, F. Robert, D. Waterhouse, K. Rowland, R. Ansari, R. Lilenbaum, and R. B. Natale Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer Ann. Onc., July 1, 2005; 16(7): 1069 - 1075. [Abstract] [Full Text] [PDF]

				K. Matsuo, K. Hotta, and H. Ueoka They Also Serve Who Only Stand and Wait: Do Individual Clinical Researchers, Too? Hoping for Individual Patient Data As Public Domain J. Clin. Oncol., February 20, 2005; 23(6): 1334 - 1335. [Full Text] [PDF]

				K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials Ann. Onc., December 1, 2004; 15(12): 1782 - 1789. [Abstract] [Full Text] [PDF]

				P. Piedbois and M. Buyse Meta-Analyses Based on Abstracted Data: A Step in the Right Direction, but Only a First Step J. Clin. Oncol., October 1, 2004; 22(19): 3839 - 3841. [Full Text] [PDF]